论文部分内容阅读
目的探讨双歧三联活菌联合美沙拉嗪治疗溃疡性结肠炎患者的临床效果。方法回顾性分析2012年10月至2014年10月辽宁省锦州市中心医院收治的溃疡性结肠炎患者90例,按随机数字表法将其分为对照组和观察组,各45例。对照组患者口服美沙拉嗪,观察组患者在对照组基础上口服双歧三联活菌,比较两组患者临床疗效及治疗前后丙二醛(MDA)、超氧化物歧化酶(SOD)、C反应蛋白(CRP)水平、不良反应发生情况。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者的MDA、CRP水平均明显低于对照组,SOD水平明显高于对照组,差异均有统计学意义(均P<0.05)。结论采用双歧三联活菌联合美沙拉嗪治疗溃疡性结肠炎,可有效改善患者临床症状及相关指标,且不良反应较少。
Objective To investigate the clinical efficacy of bifidobacterium triple combined with mesalazine in the treatment of patients with ulcerative colitis. Methods Ninety patients with ulcerative colitis admitted to Central Hospital of Jinzhou, Liaoning Province from October 2012 to October 2014 were retrospectively analyzed. According to the random number table, they were divided into control group and observation group, 45 cases each. The patients in the control group were treated with mesalazine orally, and the patients in the observation group were given oral live bifidobacterium via the control group. The clinical efficacy and the changes of malondialdehyde (MDA), superoxide dismutase (SOD), C reaction Protein (CRP) levels, adverse reactions occurred. Results The total effective rate of observation group was significantly higher than that of control group, the difference was statistically significant (P <0.05). After treatment, the levels of MDA and CRP in observation group were significantly lower than those in control group, and the SOD level was significantly higher than that of control group Group, the differences were statistically significant (all P <0.05). Conclusion Bifidobacterium triple combined live mesalazine treatment of ulcerative colitis, can effectively improve the clinical symptoms and related indicators, and fewer adverse reactions.